Constipation Clinical Trial
Official title:
National Study, Phase III, Parallel, Double Blind, Placebo Comparative and Randomized to Evaluate the Therapeutic Efficacy and Tolerability of the Combination Naturetti® (Cassia Fistula + Senna Alexandrina Miller) in the Chronic Functional Constipation
Verified date | October 2012 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Brazil: National Health Surveillance Agency |
Study type | Interventional |
Primary Objective:
- To evaluate the clinical efficacy of Naturetti (jelly sugar free)
- To test medication on subjects who suffer chronic functional constipation in 30 days
use.
Secondary Objectives:
- To demonstrate the clinical tolerability when daily used (repeated doses) of the
components of the study drug. The components will be evaluated by the adverse events
occurrence classified by possibly related, probably related and definitely related
- To demonstrate the clinical tolerability of the study medication by the continuous use
during the second phase study
- To identify any adverse events related to the study drug
- To identify any drug interaction.
Status | Completed |
Enrollment | 117 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 59 Years |
Eligibility |
Inclusion criteria: - Having chronic functional constipation by ROME IIII criteria - Having the majority of the stool as type 1 or 2 by Bristol Stool Scale - Female subjects should be using an effective contraceptive method more than 3 months if they are sexually active and on reproductive stage - ICF signature - Be able to understand and agree to undertake the study procedures - Having no contraindication related to the study drug - To perform all study visits. Exclusion criteria: - Having previous history or current neurological disorder and/or metabolic one - Having constipation caused by previous surgery - Having intestinal obstruction including colon/rectum cancer - Having endocrine disorder as diabetes mellitus - Having Irritable bowel syndrome or inflammatory bowel disease - Having multiple sclerosis - Having Parkinsons disease - Having Hirschsprungs disease and dyssynergy defecation - Continuous treatment with the following: analgesics, anticholinergic (antihistamines, antispasmodics, antidepressants, antipsychotics) iron supplements or aluminum, opiates, antihypertensive, calcium channel blockers and ganglionic blocker - Treatment with any other laxative medication other than the rescue medication during the study - Patients who could not confirm the chronic functional constipation during the phase I study - Pregnancy or breast feeding woman - Abnormal laboratory results, or clinical result that shows significant by the Investigator - Corporeal mass index > 30 - Patients who have participate in other clinical study within 30 days - Unable to fulfill the questionnaire (diary) - Any condition that makes impossible to the patient in participates by Investigator opinion. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | Sanofi-Aventis Administrative Office | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure of the chronic functional constipation symptoms based on the Rome III criteria | From the baseline to the end of the study (at 30 days) | No | |
Secondary | Evaluation of the stool aspect based on the Bristol Stool Scale | From the baseline to the end of the study (at 30 days) | No | |
Secondary | Evaluation of the use of sene extract as rescue medication | From the baseline to the end of the study (at 30 days) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
Completed |
NCT01607060 -
Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.
|
Phase 3 |